Aaron Hansen, BSc, MBBS, FRACP, on the mechanism of action for 212Pb-ADVC001

In an interview with Urology Times® at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, Aaron R. Hansen, BSc, MBBS, FRACP, described the mechanism of action for 212Pb-ADVC001.

According to Hansen, 212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy (RLT) being developed for patients with PSMA-positive metastatic castration-resistant prostate cancer. The agent is currently being assessed in the TheraPb trial (NCT05720130).¹

Hansen is a medical oncologist and the medical director at the Princess Alexandra Hospital in Brisbane, Australia.

During the discussion, Hansen highlighted 2 key properties of alpha radiation: it is highly energetic, causing double-stranded DNA breaks and potent tumor cell death, and it acts over a very short distance, which helps spare surrounding healthy tissue from damage. The hope, Hansen noted, is that these properties result in a wide therapeutic window for 212Pb-ADVC001.

REFERENCE

1. Hansen AR, Pattison DA, Gan CL, et al. Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial. Presented at: European Society for Medical Oncology Congress. October 17-21, 2025. Berlin, Germany. Abstract 2388P. https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2025_abstracts/2388P.html.pdf